Quantcast

Latest photodynamic therapy Stories

2009-11-06 14:26:00

WILMINGTON, Mass., Nov. 6 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(®) (Nasdaq GM: DUSA), a dermatology company that is developing and marketing Levulan(®) Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, announced that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the Merriman Curhan Ford Investor Summit 2009 on Tuesday, November 10, 2009 at 10:00 a.m. ET at...

2009-10-28 05:30:00

WILMINGTON, Mass., Oct. 28 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.® (Nasdaq GM: DUSA), a specialty pharmaceutical company focused on dermatology, announced today that global sales volumes of the Levulan® Kerastick®, an integral part of the Levulan® Photodynamic Therapy (PDT) technology platform, surpassed one million units. "The achievement of this milestone signifies that dermatologists in the U.S. and...

2009-10-19 05:30:00

RECEIVES EXCLUSIVE U.S. RIGHTS AND WILL RECEIVE A ROYALTY ON SALES OUTSIDE THE U.S. VANCOUVER, Oct. 19 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) ("QLT" or the "Company") today announced that it has restructured its agreement with Novartis Pharma AG ("Novartis") to simplify the relationship, under which, effective January 1, 2010, it will, among other things, receive exclusive U.S. rights to the Visudyne(R) patents to sell and market Visudyne in the U.S. Visudyne, a...

2009-10-14 05:00:00

ST. LOUIS and COLUMBUS, Ohio, Oct. 14 /PRNewswire/ -- The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) has entered into a contract with Global Vision Technologies (GVT) to create and deliver a new, web-based Photo Dynamic Therapy patient registry solution -- ClinicalPURSUIT -- to help streamline the data collection and outcomes analysis process. Photodynamic therapy (PDT) is a treatment...

2009-10-05 06:10:00

A combination of medications and a particular light therapy is effective at treating certain types of head and neck cancers in subtropical climates. In a paper presented at the 2009 American Academy of Otolaryngology "“ Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting & OTO EXPO in San Diego, researchers from the University of Miami presented findings from a study on dysplasia and carcinomas of the head and neck. It analyzed the effect of photodynamic therapy (PDT), a...

2009-10-04 11:30:00

PHOENIX, Oct. 4 /PRNewswire/ -- The appearance of facial acne scars showed greater improvement with a combination treatment of photodynamic therapy (PDT) and percutaneous collagen induction (PCI or medical needling) with the ENVIRON® Surgical Roll-CIT(TM) compared to PDT alone. The results of the pilot split-face comparison were presented by Hilton Kaplan, MD PhD, Medical Advisor for ENVIRON® distributor DermoGenesis, at the 2009 Joint Annual...

2009-08-11 05:30:00

WILMINGTON, Mass., Aug. 11 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.((R)) (NASDAQ GM: DUSA), a dermatology company that is developing and marketing Levulan((R)) Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, reported today its corporate highlights and financial results for the second quarter ended June 30, 2009. (Logo: http://www.newscom.com/cgi-bin/prnh/20090810/DC59366LOGO) Financial highlights for the second quarter and first...

2009-06-16 11:31:36

Chemists at the University of California, Santa Cruz, have developed novel compounds that show promise for photodynamic cancer therapy, which uses light-activated drugs to kill tumor cells.The new compounds, called dye-sensitized ruthenium nitrosyls, are absorbed by cancer cells and respond to specific wavelengths of light by releasing nitric oxide, which triggers cell death."For cancer treatment, you want localized delivery of a very high concentration of nitric oxide. We've designed these...

2009-06-15 06:00:00

VANCOUVER, June 15 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) today announced that twelve-month primary analysis results from the Novartis sponsored Phase II MONT BLANC study were presented on June 14, 2009 during the 17th Congress of the European Society of Ophthalmology in Amsterdam, the Netherlands. MONT BLANC is the European study of the Novartis sponsored SUMMIT clinical trial program which investigates the efficacy and safety of combining Visudyne(R) (Novartis Pharma AG)...

2009-06-02 06:00:00

VANCOUVER, June 2 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) today announced positive twelve-month primary analysis results from the Phase II RADICAL study (Reduced Fluence Visudyne Anti-VEGF-Dexamethasone In Combination for AMD Lesions) in patients with wet age-related macular degeneration ("wet AMD"). The purpose of the study is to determine if Visudyne combined with Lucentis reduces retreatment rates compared with Lucentis monotherapy, while maintaining similar vision...


Word of the Day
tesla
  • The unit of magnetic flux density in the International System of Units, equal to the magnitude of the magnetic field vector necessary to produce a force of one newton on a charge of one coulomb moving perpendicular to the direction of the magnetic field vector with a velocity of one meter per second. It is equivalent to one weber per square meter.
This word is named for Nikola Tesla, the inventor, engineer, and futurist.